CFDE Data Portal | Search GORAB-AS1

	Label	Description
	GORAB-AS1 Gene (Entity type)	ENSG00000231407 - GORAB antisense RNA 1
	GSE226249 5 V 4 PIRFENIDONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE171692 FXN knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE67266 7 V 3 ETOPOSIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE125157 1 V 0 PICEATANNOL MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS

GORAB-AS1

ENSG00000231407 - GORAB antisense RNA 1

GSE226249 5 V 4 PIRFENIDONE HUMAN DN

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE171692 FXN knockdown 1 v 0 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 6 human up

A Gene Set from LINCS

GSE67266 7 V 3 ETOPOSIDE MOUSE UP

A Gene Set from LINCS

GSE125157 1 V 0 PICEATANNOL MOUSE UP

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 0 v 6 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.